Skip to main content

Notice for elexacaftor/tezacaftor/ivacaftor (Vertex Pharmaceuticals Australia Pty Ltd)

Active ingredients
elexacaftor/tezacaftor/ivacaftor
Date of review outcome
Lapse date
Type
Orphan drug
Indication
Indicated for the treatment of cystic fibrosis (CF)
Therapeutic area
Respiratory

Help us improve the Therapeutic Goods Administration site